Phacilitate Washington 2014 at a glance: 500+

The single best cell and
gene therapy conference.
David Ichikawa, Sangamo BioSciences, Inc.
January 27-29 2014, The Grand Hyatt, Washington, DC
Incorporating
10th
Annivers
a
ry
Phacilitate Washington
2014 at a glance:
500+ Attendees
Great learning experience from
the most experienced organizations in
the immunotherapy field. If networking
and learning are you objectives, this is
the place for you.
Josh Ludwig, Wilson Wolf
Definitely the best meeting we
have attending in the last year where
we could find potential
pharma/biotech clients.
John R. Jaskowiak, Angiocrine Bioscience, Inc.
150+ Speakers
14 Hours of dedicated
informal networking time
300 organizations in
attendance from 23 countries
76% of attendees at Director
level or above.
www.bioleaders-forum.com
January 27-29 2014,
The Grand Hyatt, Washington, DC
TOP SPEAKERS INCLUDED:
Araz Raoof, (BSc Pharmacy), PhD, MBA, Vice President,
Global Functional Head CREATe (Community of
Research Excellence & Advanced Technology), Janssen
Research & Development, A division of Janssen
Pharmaceutica NV
Jan Thirkettle, BSc, PhD, Head Advanced Therapy
Delivery, GlaxoSmithKline Medicines Research Centre
Dr Robin Robinson, Director, Biomedical Advanced
Research and Development Authority (BARDA), Office of
the Assistant Secretary for Preparedness and Response
(ASPR), US Department of Health and Human Services
(HHS)
Dr Christian W. Mandl, MD, PhD, Vice President, Head of
Early & Exploratory Clinical Development, Novartis
Vaccines & Diagnostics, Inc
Dr Manuel Litchman, Vice President & Head, Oncology
Business Development & Licensing, Novartis
Dr Ronald Peck, Vice President, Global Development
Lead Yervoy, Bristol-Myers Squibb
Dr Devyn Smith, Chief Operating Officer, Neusentis
Research Unit, Pfizer Inc
Dr Klaus Bosslet, Head, Discovery Oncology Penzberg,
Pharmaceutical Research & Development (pRED),
Roche Diagnostics GmbH
Dr Johan Van Hoof, Global Therapeutic Area Head,
Infectious Diseases & Vaccines, Janssen Research &
Development, LLC; Managing Director, Crucell
Carole A. Heilman, PhD, Director, Division of Microbiology
and Infectious Diseases (DMID), NIAID, NIH
Dr Robert F. Willenbucher, Head of Cell Therapy, Janssen
Research & Development, LLC
Peter F. Bross, MD, Medical Review Officer, Office of
Cellular, Tissue & Gene Therapy (OCTGT), CBER, The Food
& Drug Administration
Dr Rajeev Venkayya, Executive Vice President & Head of
the Vaccine Business, Takeda Pharmaceuticals
Gregory MacMichael, PhD, Global Head of Advanced
Therapies, Technology Research & Development,
Novartis Pharma AG
Marian W. Wentworth, Vice President, Global Vaccine
Strategy & Innovation, Merck
Stewart Abbot PhD, Executive Director Integrative
Research, Celgene Cellular Therapeutics
Dr Paula Salmikangas, Vice-Chair, Committee for
Advanced Therapies (CAT), EMA & Senior Researcher,
Finnish Medicines Agency (FIMEA)
Solomon Langermann, PhD, Senior Vice President, R&D &
CSO, Amplimmune, Inc
Mitchell H. Finer, PhD, Chief Scientific Officer, bluebird bio
Roman M. Chicz, PhD, Head of Global External Research
& Development, Sanofi Pasteur
Dr Mahendra Rao, Director, NIH Center for Regenerative
Medicine; Laboratory Chief, Laboratory of Stem Cell
Biology, NIH
Thomas Davis, MD, Chief Medical Officer & Senior Vice
President, Clinical Development, Celldex Therapeutics
Donald W. Fink, Jr, PhD, Division of Cellular & Gene
Therapies, Office of Cellular, Tissue & Gene Therapies
(OCTGT), CBER, The Food & Drug Administration
Dr Akira Homma, President, Strategy & Policy Council,
Bio-Manguinhos / Fiocruz
Dr Michel Sadelain, Director, Center for Cell Engineering,
Memorial Sloan Kettering Cancer Center, NY
Dr Robert Tighe, Associate Director,
ImmunoPharmacology, EMD Serono, Inc
www.bioleaders-forum.com
January 27-29 2014,
The Grand Hyatt, Washington, DC
GENERAL EVENT OVERVIEW
Phacilitate Washington celebrated its 10th Anniversary in
great style, with a record attendance and overall approval
rating for the event.
The Cell & Gene Therapy Forum cemented its status as the
world’s premier event for the sector’s senior decision-makers.
The addition of the Immunotherapy Forum – focused
exclusively on active immunotherapeutic technologies –
proved to be a great success given the substantial crossover
between the two. Indeed, the two sessions which were
shared between C&GT and Immunotherapy programmes –
covering CARs and cancer vaccines respectively– were
among the best received of the meeting.
The 13th Annual Phacilitate Vaccine Forum continued to
drive the agenda for industry, Government and NGO leaders
from the prophylactic vaccine field. Last, but not least, The
Stem Cells as Discovery Research Tools event also enjoyed a
successful launch, representing another welcome foray into
a complementary technology area.
Summary of evaluation form feedback
(Marks are average out of 5)
The event overall: ............4.16 (83.2%)
The Grand Hyatt Hotel: ....................................4.42
Audio-Visual: ......................................................4.52
Phacilitate customer service (pre-event): ......4.68
Phacilitate customer service (on-site): ..........4.82
External stakeholders
included:
Aeras • Alliance for Regenerative Medicine •
Bio-Manguinhos / Fiocruz • Biotechnology
Industry Organization (BIO) • Boston Children's
Hospital • Butantan Institute • California Institute
for Regenerative Medicine (CIRM) •
CASMI/University of Oxford • Centre for
Commercialization of Regenerative Medicine
(CCRM) • Emory University • European
Medicines Agency (EMA) • Finnish Medicines
Agency (FIMEA) • Foundation Fighting Blindness
• Fraunhofer IME • Fred Hutchinson Cancer
Research Center • Georgetown University •
Georgia Institute of Technology • Global
Biological Standards Institute • Harvard Stem
Cell Institute • Health Sciences Authority,
Singapore • Human Stem Cells Institute •
International Stem Cell Society (STEMSO) •
Japan Science and Technology Agency •
Japanese Pharmaceuticals and Medical
Devices Agency (PMDA) • Johns Hopkins
University School of Medicine • Malaria Vaccine
Initiative • McGill University • MD Anderson
Cancer Center • Memorial Sloan Kettering
Cancer Center, NY • MSD Wellcome Trust
Hilleman Laboratories PVT. LTD. • National
Disease Research Interchange • NIH • NIST • NY
Stem Cell Foundation • Ottawa Hospital
Research Institute • PACT • PAHO/WHO • PATH
• Royal College of Surgeons in Ireland •
Southern Illinois University School of Medicine •
The New York Stem Cell Foundation • The Stop
ALD Foundation • Tokyo Medical University •
University of Maryland School of Medicine •
University Of Pennsylvania • University of Sussex
• University of Tampere / BioMediTech •
University of Texas Health Science Center at
Houston • US Department of Health and Human
Services (HHS) • US FDA • Yale Cancer Center •
ATTENDEE OVERVIEW
Organisation type:
53%
29%
8%
4%
2%
2%
2%
Pharma and biotech
CMOs/CROs/tool and
technology providers
Govt/regulator/NGO
Academia
Consultant
Press
Other
www.bioleaders-forum.com
Seniority:
23%
24%
29%
21%
3%
CXO/President/
Board member/
Chairman/
Managing Director
EVP/SVP/VP
Exec. Director/
Senior Director/
Director/ Partner
Senior
Manager/Manager
Other
January 27-29 2014,
The Grand Hyatt, Washington, DC
The event featured
a number of other ‘firsts’
and records
for Phacilitate:
• The launch of the annual
Bioleaders Power 10 award
at our Gala Dinner (attended
by around 200 attendees).
The inaugural award was
presented to Dr Anthony
Fauci, Director of NIAID, NIH.
His award was accepted on
his behalf by Dr Carole
Heilman, Director of DMID.
• Overall, Phacilitate
Washington attracted well
over 500 attendees to
Washington, DC.
• 60 sponsors and exhibitors
supported the event
Pharma and biotech companies at Phacilitate
Washington included:
Adaptimmune • Advantagene, Inc. • Amplimmune • apceth GmbH & Co. KG • Areta
International Srl • Argos Therapeutics • Artificial Cell Technologies • ASKLEPIOS
BioPharmaceutical, Inc • Astellas Pharma • Asterias Biotherapeutics, Inc • Athersys, Inc
• Bavarian Nordic • Baxter Healthcare Corporation • Bellicum Pharmaceuticals •
Benitec Biopharma • Biogen Idec • Biovest International • bluebird bio • Bristol-Myers
Squibb • Celgene Cellular Therapeutics • Celladon Corporation • Celldex
Therapeutics • Cellectis • Cellular Dynamics International (CDI) • Cellular Technology
Ltd. (C.T.L.) • Compugen • Crucell • CureVac GmbH • Cytograft Tissue Engineering •
Cytomedix, Inc • Daiichi Sankyo • DBV Technologies • EMD Serono • Emergent
Biosolutions • Fibrocell Science, Inc. • Gamida Cell Ltd • Genable Technologies Limited
• Genentech • Généthon • GenVec, Inc. • GeoVax • GlaxoSmithKline •
GlaxoSmithKline Biologicals • GRICEL SA • Hemostemix • immatics biotechnologies •
Immune Design • Immunovaccine • ISA Therapeutics BV • Janssen Pharmaceutical
companies of Johnson & Johnson • Jennerex Biotherapeutics • Juno Therapeutics, Inc.
• Kiadis Pharma • Lentigen Corporation • Lion Biotechnologies, Inc • Matrivax R&D
Corp • Memcine • Merck & Co, Inc • Mesoblast • MolMed S.p.A. • NanoBio
Corporation • Nanotherapeutics, Inc. • NeoStem, Inc • NexImmune, Inc. • Northwest
Biotherapeutics • Novartis Pharma • Novartis Vaccines and Diagnostics • Novavax •
Oncos Therapeutics • Oncothyreon • Opexa Therapeutics, Inc • ORCA Therapeutics •
Organogenesis Inc • Orgenesis Inc • PaxVax • PBS Biotech, Inc. • PCI Biotech AS •
Pfizer • Pluristem Therapeutics Inc. • Profectus BioSciences, Inc. • PROMETHERA
Biosciences SA/NV • Protein Sciences • ProTherImmune • ReGenX Biosciences •
Ribological GmbH • Roche Diagnostics GmbH • Sangamo BioSciences • Sanofi •
Sanofi Pasteur • Selecta Biosciences • Shire Pharmaceuticals • Smith & Nephew
Biotherapeutics • Spark Therapeutics • Stallergenes • SutroVax Inc • Takeda
Pharmaceuticals • TissueGene, Inc • Tocagen • TxCell SA • Vaccinogen, Inc •
Vedantra Pharmaceuticals • Vital Therapies, Inc.
Sponsors & exhibitors included:
Platinum sponsors
Gold sponsors
Silver sponsors
Bronze sponsors
Literature Sponsor
Technology Spotlight Sponsor
Exhibitors
Media Partners
www.bioleaders-forum.com
Associate sponsor
SPONSORS AND EXHIBITORS
ALREADY BOOKED FOR 2015
INCLUDE:
2015
SAVE THE DATE
THE GRAND HYATT WASHINGTON, DC
JANUARY 26TH-28TH
WHAT’S HAPPENING IN 2015?
•
•
•
•
•
Have your say on these ideas,
or confirm your involvement –
contact Phacilitate today!
For information on sponsorship
and/or exhibiting:
Michael Adeniya, Business Development Director
t: +44 (0) 7384 7951
e: [email protected]
For delegate enquiries:
•
Expanded Cell & Gene Therapy Forum and Immunotherapy
Forum agendas, including dedicated 3-days streams
focusing on manufacturing business models and
technologies, R&D/clinical development, logistics,
regulatory affairs and more
New app-based pre-event online networking service
Largest ever speaker panel – expect well over 150
bioleaders
Annual Gala Awards Dinner
Redesigned and expanded exhibition area
Novel formats that we are looking to build into the
conference agenda include:
– Interactive ‘Meet the Professor’ sessions – academic opinion
leaders in open Q&A
– Working Lunch discussions for small groups
– ‘Tech room’ demonstrations
– White paper/clinical review data sessions
– 1-on-1 regulatory ‘drop in clinics’
– Speed networking sessions
– ‘Behind Closed Doors’ Advisory Board-led summit meetings,
complete with an exclusive post-event report on conclusions
and strategic action points for participants.
Kim Evans, Programme Manager
t: +44 (0) 7384 7993
e: [email protected]
For input regarding content and format for
the agenda, and event as a whole:
David McCall, Portfolio Director
t: +44 (0)20 7384 8050
e: [email protected]
For marketing enquiries:
Carina Hunter, Marketing Manager
e: [email protected]
t: +44 (0)20 7384 7897
www.bioleaders-forum.com